Butorphanol in Pain Following Ablation for Hepatic Tumor

B

Bibo Wang

Status

Completed

Conditions

Visceral Pain
Microwave Ablation
Hepatic Tumor

Treatments

Drug: normal saline
Drug: Butorphanol

Study type

Interventional

Funder types

Other

Identifiers

NCT06031129
Jinling WBB

Details and patient eligibility

About

The objective of this investigation was to evaluate the influence of Butorphanol on postoperative pain mitigation in patients undergoing microwave ablation for hepatic tumor. Employing a rigorously designed multicentral, randomized, and placebo-controlled format, patients subjected to microwave ablation were assigned randomly to either Butorphanol (experimental group) or normal saline (control group). Primary outcomes encompassed intraoperative pain levels assessed through patient-driven evaluation utilizing a 10-point visual analog scale (VAS). Secondary outcomes included postoperative pain levels at the 6-hour mark (VAS) and comprehensive pain assessment outcomes.

Enrollment

300 patients

Sex

All

Ages

20 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

patients performing Microwave Ablation sign the informed consent

Exclusion criteria

Patients with a body mass index > 30 kg/m2 a history of depression opioid dependence poorly controlled hypertension (systolic blood pressure > 180 mmHg) myocardial infarction severe liver disease significant abdominal pain before surgery patients with sensory system or language dysfunctions who could not cooperate to complete the scale pregnant women.

Trial design

300 participants in 2 patient groups, including a placebo group

Butorphanol
Experimental group
Treatment:
Drug: Butorphanol
normal saline
Placebo Comparator group
Treatment:
Drug: normal saline

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems